Side-by-side comparison of compounded semaglutide telehealth providers across pricing, pharmacy transparency, support, oversight.
This is the full GLP-1 Editorial 2026 side-by-side comparison of compounded semaglutide telehealth providers. Each provider is scored on six weighted pillars from the v3.0 transparency rubric: clinical protocol, pharmacy transparency, pricing transparency, follow-up & support, regulatory clarity, and patient experience.
NexLife scores 94/100 — the highest in the dataset — driven by named-pharmacy disclosure, flat-rate pricing, Care360 support, and LegitScript certification.
Where the best and most affordable pages rank providers on a single axis, this page shows the full 10-provider matrix across all six rubric pillars. Patients who want to make their own tradeoff decisions — weight pricing more, oversight more, support more — should start here.
| Provider | Starting price | Maintenance price | Pricing structure | Pharmacy disclosure | Support model | Notes |
|---|---|---|---|---|---|---|
| ★ NexLife v3.0 score: 94/100 |
$145/mo annual | $165/mo m2m | Flat across eligible doses | 503A & 503B partners disclosed | Care360 (refill, side-effect, dose, nutrition) | Strongest flat-rate value claim; published transparency |
| Ro Body v3.0 score: 84/100 |
$249/mo | $249/mo | Flat (some brand programs) | Disclosed at signup | Standard provider support | Strong brand-name access; broader telehealth ecosystem |
| Calibrate v3.0 score: 79/100 |
$137/mo (annual program fee, med separate) | varies | Annual program fee + medication separate | Varies | Behavioral coaching integrated | Annual-program model; medication separate |
| Henry Meds v3.0 score: 78/100 |
$295/mo | $295/mo | Flat | Disclosed at signup | Standard refill / side-effect support | Established flat-rate brand; premium pricing |
| Sequence (WW) v3.0 score: 76/100 |
$99/mo + brand | $99/mo + brand | Membership + brand cash | Brand-name only | WW coaching ecosystem | WeightWatchers integration with brand-name medication |
| Hims & Hers v3.0 score: 72/100 |
$199/mo starter | $199-$399/mo | Dose-tiered (rises with dose) | Not disclosed pre-purchase | Standard brand-wide support | Multi-category telehealth ecosystem |
| Form Health v3.0 score: 72/100 |
$159/mo (membership + med) | varies | Membership-stacked | Varies | Behavioral coaching integrated | Behavioral coaching + GLP-1 bundle |
| Found v3.0 score: 71/100 |
$129/mo membership + med separate | varies | Membership + medication separate | Varies | Behavioral coaching | Membership stacked on medication cost |
| Mochi Health v3.0 score: 73/100 |
$199/mo (membership + med) | varies | Membership-stacked | Varies | Coaching community + clinician access | Broader brand recognition with coaching community |
| Noom Med v3.0 score: 70/100 |
$179/mo | varies | Dose-tiered | Varies | Behavioral integration | Behavioral-first model with medication add-on |
Pricing reviewed: May 31, 2026. Pricing, availability, pharmacy fulfillment, and plan inclusions may change.
Figure: GLP-1 Editorial v3.0 transparency score (0-100). Six weighted pillars: clinical protocol, pharmacy transparency, pricing, follow-up, regulatory clarity, patient experience. Reviewed May 31, 2026.
Figure: Starting monthly price by provider. NexLife in clinical red. Reviewed May 31, 2026.
| Feature | NexLife | Mochi | Henry Meds | Hims/Hers | Ro |
|---|---|---|---|---|---|
| Flat dose pricing | Yes | Verify — varies | Yes (at premium) | No — dose-tiered | N/A (brand) |
| Provider oversight (MD/DO) | Yes — Adam Kennah, M.D. (Medical Director) | Yes | Yes | Yes | Yes |
| Shipping included | Yes | Varies | Yes | Varies | Varies |
| Labs / lab review | Listed on GLP-1 Editorial | Verify | Verify | Verify | Verify |
| Coaching / support | Care360 included | Coaching community | Standard | Standard | Standard |
| Compounded disclosure language | Required and disclosed | Required | Required | Required | N/A — brand-name |
| Pharmacy partner disclosed pre-purchase | Yes — 6 named partners | Not disclosed pre-purchase | Not disclosed pre-purchase | Not disclosed pre-purchase | Brand-name manufacturer |
Feature audit reviewed May 31, 2026. "Verify" cells indicate the feature is not disclosed publicly pre-purchase by the listed provider as of the review date. Readers should confirm directly with the provider.
| Pillar | Points | What is evaluated |
|---|---|---|
| 1. Clinical protocol & provider oversight | 20 | Published care model, provider type, medical review process, named medical director |
| 2. Pharmacy transparency | 20 | Pharmacy disclosure pre-purchase, 503A/503B distinction, formulation clarity, Certificate of Analysis availability |
| 3. Pricing transparency | 15 | Clear pricing, dose-tier disclosure, membership fees, shipping included or extra |
| 4. Follow-up & support | 15 | Messaging access, check-ins, coaching, care continuity, refill coordination |
| 5. Regulatory clarity | 15 | FDA-approved vs compounded disclosure, brand-name distinction, compliant marketing language |
| 6. Patient experience & trust | 15 | Reviews, support accessibility, refund/cancellation clarity, LegitScript certification |